Revisiting ovarian cancer preclinical models: Implications for a better management of the disease

Cancer Treatment Reviews

Volumn 39, Issue 6, 2013, Pages 561-568

  Ricci, Francesca ^a   Broggini, Massimo ^a   Damia, Giovanna ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

GEM models; Ovarian preclinical models; Xenografts

Indexed keywords

ANGIOGENESIS; CANCER GROWTH; EPITHELIUM; HUMAN; METASTASIS; NONHUMAN; OVARY CARCINOMA; OVARY SURFACE EPITHELIUM; REVIEW; TRANSGENE; TREATMENT RESPONSE; TUMOR INVASION; TUMOR XENOGRAFT; UTERINE TUBE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84878897405     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.01.005     Document Type: Review

References (136)

1. Siegel R., Desantis C., Virgo K., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241.
2. McGuire W.P. Maintenance therapy for ovarian cancer: of helsinki and hippocrates. J Clin Oncol 2009, 27:4633-4634.
3. Coleman M.P., Forman D., Bryant H., et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377:127-138.
4. Shih Ie M., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164:1511-1518.
5. Shih Ie M., Kurman R.J. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005, 11:7273-7279.
6. Cho K.R., Shih Ie M. Ovarian cancer. Annu Rev Pathol 2009, 4:287-313.
7. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008, 9:1191-1197.
8. Kurman R.J., Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011, 42:918-931.
9. Kindelberger D.W., Lee Y., Miron A., et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007, 31:161-169.
10. Landen C.N., Birrer M.J., Sood A.K. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008, 26:995-1005.
11. Lee Y., Miron A., Drapkin R., et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007, 211:26-35.
12. King S.M., Burdette J.E. Evaluating the progenitor cells of ovarian cancer: analysis of current animal models. BMB Rep 2011, 44:435-445.
13. Vaughan S., Coward J.I., Bast R.C., et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011, 11:719-725.
14. Diaz-Padilla I., Malpica A.L., Minig L., et al. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 2012, 126:279-285.
15. Fredrickson T.N. Ovarian tumors of the hen. Environ Health Perspect 1987, 73:35-51.
16. Barua A., Bitterman P., Abramowicz J.S., et al. Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer. Int J Gynecol Cancer 2009, 19:531-539.
17. Hakim A.A., Barry C.P., Barnes H.J., et al. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila) 2009, 2:114-121.
18. Nofech-Mozes S., Khalifa M.A., Ismiil N., et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol 2008, 21:1147-1155.
19. Nowee M.E., Dorsman J.C., Piek J.M., et al. HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. Histopathology 2007, 51:666-673.
20. Marr-Belvin A.K., Bailey C.C., Knight H.L., et al. Ovarian pathology in rhesus macaques: a 12-year retrospective. J Med Primatol 2010, 39:170-176.
21. Moore C.M., Hubbard G.B., Leland M.M., et al. Spontaneous ovarian tumors in twelve baboons: a review of ovarian neoplasms in non-human primates. J Med Primatol 2003, 32:48-56.
22. Cline J.M., Wood C.E., Vidal J.D., et al. Selected background findings and interpretation of common lesions in the female reproductive system in macaques. Toxicol Pathol 2008, 36:142-163.
23. Cooper T.K., Gabrielson K.L. Spontaneous lesions in the reproductive tract and mammary gland of female non-human primates. Birth Defects Res B Dev Reprod Toxicol 2007, 80:149-170.
24. Gregson R.L., Lewis D.J., Abbott D.P. Spontaneous ovarian neoplasms of the laboratory rat. Vet Pathol 1984, 21:292-299.
25. Tillmann T., Kamino K., Mohr U. Incidence and spectrum of spontaneous neoplasms in male and female CBA/J mice. Exp Toxicol Pathol 2000, 52:221-225.
26. Sharrow A.C., Ronnett B.M., Thoburn C.J., et al. Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats. J Ovarian Res 2010, 3:9.
27. Connolly D.C. Animal models of ovarian cancer. Cancer Treat Res 2009, 149:353-391.
28. Adams A.T., Auersperg N. Transformation of cultured rat ovarian surface epithelial cells by kirsten murine sarcoma virus. Cancer Res 1981, 41:2063-2072.
29. Hoffman A.G., Burghardt R.C., Tilley R., et al. An in vitro model of ovarian epithelial carcinogenesis: changes in cell-cell communication and adhesion occurring during neoplastic progression. Int J Cancer 1993, 54:828-838.
30. Kido M., Shibuya M. Isolation and characterization of mouse ovarian surface epithelial cell lines. Pathol Res Pract 1998, 194:725-730.
31. Foulkes W.D. Of mice and women. Cancer Cell 2002, 1:11-12.
32. Kleihues P., Schauble B., Zur Hausen A., et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997, 150:1-13.
33. Davies B.R., Auersperg N., Worsley S.D., et al. Transfection of rat ovarian surface epithelium with erb-B2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo. Am J Pathol 1998, 152:297-306.
34. Schumacher J.J., Dings R.P., Cosin J., et al. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res 2007, 67:3683-3690.
35. Gregoire L., Rabah R., Schmelz E.M., et al. Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro. Clin Cancer Res 2001, 7:4280-4287.
36. Tsao S.W., Mok S.C., Fey E.G., et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995, 218:499-507.
37. Liu J., Yang G., Thompson-Lanza J.A., et al. A genetically defined model for human ovarian cancer. Cancer Res 2004, 64:1655-1663.
38. Orsulic S., Li Y., Soslow R.A., et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002, 1:53-62.
39. Xing D., Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 2006, 66:8949-8953.
40. Karst A.M., Levanon K., Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 2011, 108:7547-7552.
41. Shan W., Mercado-Uribe I., Zhang J., et al. Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle 2012, 11:2107-2113.
42. Hanahan D., Wagner E.F., Palmiter R.D. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 2007, 21:2258-2270.
43. Garson K., Macdonald E., Dube M., et al. Generation of tumors in transgenic mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1. J Soc Gynecol Investig 2003, 10:244-250.
44. Kananen K., Markkula M., Rainio E., et al. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol Endocrinol 1995, 9:616-627.
45. Keri R.A., Lozada K.L., Abdul-Karim F.W., et al. Luteinizing hormone induction of ovarian tumors: oligogenic differences between mouse strains dictates tumor disposition. Proc Natl Acad Sci USA 2000, 97:383-387.
46. Rahman N.A., Kananen Rilianawati K., Paukku T., et al. Transgenic mouse models for gonadal tumorigenesis. Mol Cell Endocrinol 1998, 145:167-174.
47. Connolly D.C., Bao R., Nikitin A.Y., et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003, 63:1389-1397.
48. Hensley H., Quinn B.A., Wolf R.L., et al. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther 2007, 6:1717-1725.
49. Daikoku T., Tranguch S., Trofimova I.N., et al. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 2006, 66:2527-2531.
50. Mabuchi S., Altomare D.A., Connolly D.C., et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007, 67:2408-2413.
51. Pieretti-Vanmarcke R., Donahoe P.K., Pearsall L.A., et al. Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci USA 2006, 103:17426-17431.
52. Pieretti-Vanmarcke R., Donahoe P.K., Szotek P., et al. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res 2006, 12:1593-1598.
53. Inoue M., Hager J.H., Ferrara N., et al. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002, 1:193-202.
54. Du Y.C., Lewis B.C., Hanahan D., et al. Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biol 2007, 5:e276.
55. Deeb K.K., Michalowska A.M., Yoon C.Y., et al. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007, 67:8065-8080.
56. Liang S., Yang N., Pan Y., et al. Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PLoS ONE 2009, 4:e4295.
57. Hengstler J.G., Bockamp E.O., Hermes M., et al. Oncogene-blocking therapies: new insights from conditional mouse tumor models. Curr Cancer Drug Targets 2006, 6:603-612.
58. Meuwissen R., Berns A. Mouse models for human lung cancer. Genes Dev 2005, 19:643-664.
59. Ahmad I., Sansom O.J., Leung H.Y. Advances in mouse models of prostate cancer. Expert Rev Mol Med 2008, 10:e16.
60. Xu X., Wagner K.U., Larson D., et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999, 22:37-43.
61. Jonkers J., Meuwissen R., Van der Gulden H., et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001, 29:418-425.
62. Karreth F.A., Frese K.K., DeNicola G.M., et al. C-Raf is required for the initiation of lung cancer by KRAS (G12D). Cancer Discov 2011, 1:128-136.
63. Jackson E.L., Willis N., Mercer K., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic KRAS. Genes Dev 2001, 15:3243-3248.
64. Tuveson D.A., Zhu L., Gopinathan A., et al. Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res 2006, 66:242-247.
65. Chodankar R., Kwang S., Sangiorgi F., et al. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 2005, 15:561-565.
66. Clark-Knowles K.V., Garson K., Jonkers J., et al. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 2007, 313:133-145.
67. Dinulescu D.M., Ince T.A., Quade B.J., et al. Role of KRAS and PTEN in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005, 11:63-70.
68. Flesken-Nikitin A., Choi K.C., Eng J.P., et al. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003, 63:3459-3463.
69. Wu R., Hendrix-Lucas N., Kuick R., et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/PTEN signaling pathways. Cancer Cell 2007, 11:321-333.
70. Boyd J. Mouse models of gynecologic pathology. N Engl J Med 2005, 352:2240-2242.
71. Cho K.R. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med 2009, 133:1775-1781.
72. Aunoble B., Sanches R., Didier E., et al. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000, 16:567-576.
73. Feeley K.M., Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001, 38:87-95.
74. Buller R.E., Lallas T.A., Shahin M.S., et al. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res 2001, 7:831-838.
75. Hunn J., Rodriguez G.C. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012, 55:3-23.
76. Bell D.A. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005, 18(Suppl 2):19-32.
77. Laviolette L.A., Garson K., Macdonald E.A., et al. 17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology 2010, 151:929-938.
78. Obata K., Morland S.J., Watson R.H., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998, 58:2095-2097.
79. Sato N., Tsunoda H., Nishida M., et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000, 60:7052-7056.
80. Sieben N.L., Macropoulos P., Roemen G.M., et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004, 202:336-340.
81. Vercellini P., Trecca D., Oldani S., et al. Analysis of p53 and ras gene mutations in endometriosis. Gynecol Obstet Invest 1994, 38:70-71.
82. Fan H.Y., Liu Z., Paquet M., et al. Cell type-specific targeted mutations of Kras and PTEN document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res 2009, 69:6463-6472.
83. Mullany L.K., Fan H.Y., Liu Z., et al. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of PTEN in a mouse model in vivo. Oncogene 2011, 30:3522-3536.
84. Kinross K.M., Montgomery K.G., Kleinschmidt M., et al. An activating Pik3ca mutation coupled with PTEN loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 2012, 122:553-557.
85. Kim J., Coffey D.M., Creighton C.J., et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 2012, 109:3921-3926.
86. Rygaard J., Povlsen C.O. Heterotransplantation of a human malignant tumour to " Nude" mice. Acta Pathol Microbiol Scand 1969, 77:758-760.
87. Shaw T.J., Senterman M.K., Dawson K., et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004, 10:1032-1042.
88. Curley M.D., Therrien V.A., Cummings C.L., et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009, 27:2875-2883.
89. Damia G., D'Incalci M. Contemporary pre-clinical development of anticancer agents - what are the optimal preclinical models?. Eur J Cancer 2009, 45:2768-2781.
90. Kelland L.R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004, 40:827-836.
91. Talmadge J.E., Singh R.K., Fidler I.J., et al. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007, 170:793-804.
92. Fiebig H.H., Maier A., Burger A.M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004, 40:802-820.
93. Alley M.C., Scudiero D.A., Monks A., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988, 48:589-601.
94. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 2009, 101:6-8.
95. Boven E., Winograd B., Berger D.P., et al. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 1992, 52:5940-5947.
96. Massazza G., Tomasoni A., Lucchini V., et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer 1989, 44:494-500.
97. Masazza G., Lucchini V., Tomasoni A., et al. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease. Cancer Res 1991, 51:6358-6362.
98. Cook N., Olive K.P., Frese K., et al. KRAS-driven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods Enzymol 2008, 439:73-85.
99. Singh M., Lima A., Molina R., et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010, 28:585-593.
100. Previdi S., Abbadessa G., Dalo F., et al. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 2012, 11:214-223.
101. Pestourie C., Theze B., Kuhnast B., et al. PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18)F]F-L-DOPA. Eur J Nucl Med Mol Imaging 2010, 37:58-66.
102. O'Neill K., Lyons S.K., Gallagher W.M., et al. Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol 2010, 220:317-327.
103. Connolly D.C., Hensley H.H. Xenograft and transgenic mouse models of epithelial ovarian cancer and non invasive imaging modalities to monitor ovarian tumor growth in situ-applications in evaluating novel therapeutic agents. Curr Protoc Pharmacol 2009, 45:141211-141226.
104. Fiebig H.H., Berger D.P., Winterhalter B.R., et al. In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts. Cancer Treat Rev 1990, 17:109-117.
105. Sausville E.A., Burger A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006, 66:3351-3354. Discussion 3354.
106. Steel G.G., Courtenay V.D., Peckham M.J. The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer 1983, 47:1-13.
107. Johnson J.I., Decker S., Zaharevitz D., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001, 84:1424-1431.
108. Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2003, 2:134-139.
109. Wu R., Hu T.C., Rehemtulla A., et al. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 2011, 17:7359-7372.
110. Santiskulvong C., Konecny G.E., Fekete M., et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 2011, 17:2373-2384.
111. O'Brien C.A., Kreso A., Jamieson C.H. Cancer stem cells and self-renewal. Clin Cancer Res. 2000, 16:3113-3120.
112. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8:545-554.
113. Zhou B.B., Zhang H., Damelin M., et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823.
114. Alison M.R., Lim S.M., Nicholson L.J. Cancer stem cells: problems for therapy?. J Pathol 2011, 223:147-161.
115. Garvalov B.K., Acker T. Cancer stem cells: a new framework for the design of tumor therapies. J Mol Med 2011, 89:95-107.
116. Mor G., Yin G., Chefetz I., et al. Ovarian cancer stem cells and inflammation. Cancer Biol Ther 2011, 11:708-713.
117. Curley M.D., Garrett L.A., Schorge J.O., et al. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 2011, 16:368-392.
118. Bapat S.A. Human ovarian cancer stem cells. Reproduction 2010, 140:33-41.
119. Ahmed N., Abubaker K., Findlay J., et al. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem 2013, 114:21-34.
120. Zhang S., Balch C., Chan M.W., et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68:4311-4320.
121. Alvero A.B., Fu H.H., Holmberg J., et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009, 27:2405-2413.
122. Gao M.Q., Choi Y.P., Kang S., et al. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680.
123. Ricci F., Bernasconi S., Perego P., et al. Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle 2012, 11:1966-1976.
124. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
125. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
126. Konstantinopoulos P.A., Spentzos D., Karlan B.Y., et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010, 28:3555-3561.
127. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
128. Audeh M.W., Carmichael J., Penson R.T., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
129. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
130. Singer G., Oldt R., Cohen Y., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95:484-486.
131. Pohl G., Ho C.L., Kurman R.J., et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005, 65:1994-2000.
132. Nakayama N., Nakayama K., Yeasmin S., et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer 2008, 99:2020-2028.
133. Farley J., Brady W., Birreer M.A. phase II trila of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. Annual meeting of AARC CT-05 2012.
134. Burger R.A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011, 121:230-238.
135. Burger R.A., Brady M.F., Bookman M.A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
136. Perren T.J., Swart A.M., Pfisterer J., et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.